{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T07:56:55Z","timestamp":1777363015856,"version":"3.51.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"15-16","license":[{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s00508-021-01812-3","type":"journal-article","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T09:14:00Z","timestamp":1612862040000},"page":"808-815","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Beneficial effect of ACE inhibitors on kidney function in polycythemia vera"],"prefix":"10.1007","volume":"133","author":[{"given":"Ivan","family":"Kre\u010dak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Mori\u0107 Peri\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Zekanovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hrvoje","family":"Holik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo\u017eena","family":"Coha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Velka","family":"Gveri\u0107-Kre\u010dak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marko","family":"Lucijani\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,8]]},"reference":[{"issue":"1","key":"1812_CR1","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/ajh.25303","volume":"94","author":"A Tefferi","year":"2019","unstructured":"Tefferi\u00a0A, Barbui\u00a0T. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. Am J Hematol. 2019;94(1):133\u201343.","journal-title":"Am J Hematol"},{"key":"1812_CR2","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1056\/NEJMoa035572","volume":"350","author":"R Landolfi","year":"2004","unstructured":"Landolfi\u00a0R, Marchioli\u00a0R, Kutti\u00a0J, Gisslinger\u00a0H, Tognoni\u00a0G, Patrono\u00a0C, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N\u00a0Engl J Med. 2004;350:114\u201324.","journal-title":"N Engl J Med"},{"key":"1812_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1208500","volume":"368","author":"R Marchioli","year":"2013","unstructured":"Marchioli\u00a0R, Finazzi\u00a0G, Specchia\u00a0G, Cacciola\u00a0R, Cavazzina\u00a0R, Cilloni\u00a0D, et\u00a0al. Cardiovascular events and intensity of treatment in polycythemia vera. N\u00a0Engl J Med. 2013;368:22\u201333.","journal-title":"N Engl J Med"},{"key":"1812_CR4","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","volume":"32","author":"T Barbui","year":"2018","unstructured":"Barbui\u00a0T, Tefferi\u00a0A, Vannucchi\u00a0AM, Passamonti\u00a0F, Silver\u00a0RT, Hoffman\u00a0R, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32:1057\u201369.","journal-title":"Leukemia"},{"key":"1812_CR5","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.leukres.2014.01.014","volume":"38","author":"AS Christensen","year":"2014","unstructured":"Christensen\u00a0AS, M\u00f8ller\u00a0JB, Hasselbalch\u00a0HC. Chronic kidney disease in patients with the Philadelphia-negative chronic myeloproliferative neoplasms. Leuk Res. 2014;38:490\u20135.","journal-title":"Leuk Res"},{"key":"1812_CR6","doi-asserted-by":"publisher","first-page":"790","DOI":"10.3904\/kjim.2016.263","volume":"33","author":"SW Baek","year":"2018","unstructured":"Baek\u00a0SW, Moon\u00a0YJ, Ryu\u00a0H, Choi\u00a0YS, Song\u00a0IK, Lee\u00a0HY, et al. Chronic kidney disease\u00a0in the\u00a0 BCR-ABL1-negative\u00a0myeloproliferative\u00a0neoplasm: a\u00a0single-center retrospective study. Korean J Intern Med. 2018;33:790\u20137.","journal-title":"Korean J Intern Med"},{"key":"1812_CR7","doi-asserted-by":"publisher","first-page":"e506","DOI":"10.3324\/haematol.2018.208876","volume":"104","author":"Y Fukuda","year":"2019","unstructured":"Fukuda\u00a0Y, Araki\u00a0M, Yamamoto\u00a0K, Morishita\u00a0S, Inano\u00a0T, Misawa\u00a0K, et\u00a0al. Evidence\u00a0for\u00a0prevention\u00a0of\u00a0renal\u00a0dysfunction\u00a0associated\u00a0with\u00a0primary\u00a0myelofibrosis\u00a0by\u00a0cytoreductive\u00a0therapy. Haematologica. 2019;104:e506\u2013e9.","journal-title":"Haematologica"},{"issue":"4","key":"1812_CR8","doi-asserted-by":"publisher","first-page":"e0150029","DOI":"10.1371\/journal.pone.0150029","volume":"11","author":"SY Han","year":"2016","unstructured":"Han\u00a0SY, Oh\u00a0SW, Hong\u00a0JW, Yi\u00a0SJ, Noh\u00a0JH, Lee\u00a0HR, et\u00a0al. Association of estimated glomerular filtration rate with hemoglobin level in Korean adults: the 2010\u20132012 korea national health and nutrition examination survey. PLoS ONE. 2016;11(4):e150029.","journal-title":"PLoS ONE"},{"issue":"1","key":"1812_CR9","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/ndt\/gfr296","volume":"27","author":"SW Oh","year":"2012","unstructured":"Oh\u00a0SW, Baek\u00a0SH, Kim\u00a0YC, Goo\u00a0HS, Chin\u00a0HJ, Na\u00a0KY, et\u00a0al. Higher hemoglobin level is associated with subtle declines in renal function and presence of cardiorenal risk factors in early CKD stages. Nephrol Dial Transplant. 2012;27(1):267\u201375.","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"1812_CR10","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.leukres.2005.12.018","volume":"30","author":"HC Hasselbalch","year":"2006","unstructured":"Hasselbalch\u00a0HC, Riley\u00a0CH. Statins\u00a0in the treatment of polycythaemia vera and allied\u00a0disorders: an antithrombotic and cytoreductive potential? Leuk Res. 2006;30(10):1217\u201325.","journal-title":"Leuk Res"},{"issue":"2","key":"1812_CR11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/bjh.12103","volume":"160","author":"LN Griner","year":"2016","unstructured":"Griner\u00a0LN, McGraw\u00a0KL, Johnson\u00a0JO, List\u00a0AF, Reuther\u00a0GW. JAK2-V617F-mediated signalling is dependent on lipid rafts and\u00a0statins\u00a0inhibit JAK2-V617F-dependent cell growth. Br J Haematol. 2016;160(2):177\u201387.","journal-title":"Br J Haematol"},{"key":"1812_CR12","first-page":"20","volume":"6","author":"AE S\u00f8rensen","year":"2016","unstructured":"S\u00f8rensen\u00a0AE, Kallenbach\u00a0K, Hasselbalch\u00a0HC. A remarkable hematological and molecular response pattern in a\u00a0patient with polycythemia vera during combination therapy with simvastatin and alendronate. Leuk Res Rep. 2016;6:20\u20133.","journal-title":"Leuk Res Rep"},{"issue":"4","key":"1812_CR13","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s00277-020-03950-6","volume":"99","author":"I Kre\u010dak","year":"2020","unstructured":"Kre\u010dak\u00a0I, Holik\u00a0H, Mori\u0107-Peri\u0107\u00a0M, Zekanovi\u0107\u00a0I, Coha\u00a0B, Gveri\u0107-Kre\u010dak\u00a0V. The impact of statins on the intensity of phlebotomies in polycythemia vera. Ann Hematol. 2020;99(4):911\u20132.","journal-title":"Ann Hematol"},{"key":"1812_CR14","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.amjcard.2014.05.033","volume":"114","author":"Q Geng","year":"2014","unstructured":"Geng\u00a0Q, Ren\u00a0J, Song\u00a0J, Li\u00a0S, Chen\u00a0H. Meta-analysis of the effect of statins on renal function. Am J Cardiol. 2014;114:562\u201370.","journal-title":"Am J Cardiol"},{"key":"1812_CR15","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.ahj.2010.08.012","volume":"160","author":"G Sharp Collaborative","year":"2010","unstructured":"Sharp Collaborative\u00a0G. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438\u00a0patients with chronic kidney disease. Am Heart\u00a0J. 2010;160:785\u2013794.e10.","journal-title":"Am Heart J"},{"issue":"7","key":"1812_CR16","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1136\/jcp.2003.014282","volume":"57","author":"B Afzali","year":"2005","unstructured":"Afzali\u00a0B, Goldsmith\u00a0DJ. Beneficial effects of statins on the kidney. J\u00a0Clin Pathol. 2004;57(7):673\u20134.","journal-title":"J Clin Pathol"},{"issue":"1","key":"1812_CR17","doi-asserted-by":"publisher","first-page":"16632","DOI":"10.1038\/s41598-019-53064-x","volume":"9","author":"K Esmeijer","year":"2019","unstructured":"Esmeijer\u00a0K, Dekkers\u00a0OM, de Fijter\u00a0JW, Dekker\u00a0FW, Hoogeveen\u00a0EK. Effect of different types of statins on kidney function decline and proteinuria: a\u00a0network meta-analysis. Sci Rep. 2019;9(1):16632.","journal-title":"Sci Rep"},{"issue":"Suppl 1","key":"1812_CR18","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1681\/ASN.2004110968","volume":"16","author":"C Chiurchiu","year":"2005","unstructured":"Chiurchiu\u00a0C, Remuzzi\u00a0G, Ruggenenti\u00a0P. Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses. J\u00a0Am Soc Nephrol. 2005;16(Suppl 1):S58\u2013S63.","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl 1","key":"1812_CR19","first-page":"27","volume":"15","author":"M Baltatzi","year":"2011","unstructured":"Baltatzi\u00a0M, Savopoulos\u00a0Ch, Hatzitolios\u00a0A. Role of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in hypertension of chronic kidney disease and renoprotection. Study results. Hippokratia. 2011;15(Suppl 1):27\u201332.","journal-title":"Hippokratia"},{"issue":"4","key":"1812_CR20","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1046\/j.1523-1755.2003.00850.x","volume":"63","author":"DV Vlahakos","year":"2003","unstructured":"Vlahakos\u00a0DV, Marathias\u00a0KP, Agroyannis\u00a0B, Madias\u00a0NE. Posttransplant erythrocytosis. Kidney Int. 2003;63(4):1187\u201394.","journal-title":"Kidney Int"},{"issue":"1","key":"1812_CR21","first-page":"57","volume":"20","author":"R Esposito","year":"2007","unstructured":"Esposito\u00a0R, Giammarino\u00a0A, De Blasio\u00a0A, Martinelli\u00a0V, Cirillo\u00a0F, Scopacasa\u00a0F, et al. Ramipril in post-renal transplant erythrocytosis. J\u00a0Nephrol. 2007;20(1):57\u201362.","journal-title":"J Nephrol"},{"issue":"3","key":"1812_CR22","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/0272-6386(95)90496-4","volume":"26","author":"M Perazella","year":"1995","unstructured":"Perazella\u00a0M, McPhedran\u00a0P, Kliger\u00a0A, Lorber\u00a0M, Levy\u00a0E, Bia\u00a0MJ. Enalapril treatment of posttransplant erythrocytosis: efficacy independent of circulating erythropoietin levels. Am J Kidney Dis. 1995;26(3):495\u2013500.","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"1812_CR23","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.4161\/cbt.6.9.4568","volume":"6","author":"MM Vrsalovic","year":"2007","unstructured":"Vrsalovic\u00a0MM, Pejsa\u00a0V, Veic\u00a0TS, Ostojic Kolonic\u00a0S, Ajdukovic\u00a0R, Haris\u00a0V, et al. Bone marrow renin-angiotensin system expression in polycythemia vera and essential thrombocythemia depends on JAK2 mutational status. Cancer Biol Ther. 2007;6(9):1434\u20136.","journal-title":"Cancer Biol Ther"},{"issue":"19","key":"1812_CR24","first-page":"4089","volume":"20","author":"IC Haznedaroglu","year":"2016","unstructured":"Haznedaroglu\u00a0IC, Malkan\u00a0UY. Local bone marrow renin-angiotensin system in the genesis of leukemia and other malignancies. Eur Rev Med Pharmacol Sci. 2016;20(19):4089\u2013111.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"1","key":"1812_CR25","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1600-0609.1996.tb00503.x","volume":"57","author":"S Nomura","year":"1996","unstructured":"Nomura\u00a0S, Sugihara\u00a0T, Tomiyama\u00a0T, Kitano\u00a0Y, Yawata\u00a0Y, Osawa\u00a0G. Polycythaemia vera: response to treatment with angiotensin-converting enzyme inhibitor. Eur J Haematol. 1996;57(1):117\u20139.","journal-title":"Eur J Haematol"},{"issue":"9","key":"1812_CR26","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1182\/blood-2016-11-752600","volume":"129","author":"T Barbui","year":"2017","unstructured":"Barbui\u00a0T, Masciulli\u00a0A, Ghirardi\u00a0A, Carobbio\u00a0A. ACE inhibitors and cytoreductive therapy in polycythemia vera. Blood. 2017;129(9):1226\u20137.","journal-title":"Blood"},{"key":"1812_CR27","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber\u00a0DA, Orazi\u00a0A, Hasserjian\u00a0R, Thiele\u00a0J, Borowitz\u00a0MJ, Le Beau\u00a0M, et\u00a0al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"1812_CR28","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3389\/fcell.2019.00314","volume":"7","author":"M Provenzano","year":"2019","unstructured":"Provenzano\u00a0M, Coppolino\u00a0G, de Nicola\u00a0L, Serra\u00a0R, Garofalo\u00a0C, Andreucci\u00a0M, et\u00a0al. Unraveling cardiovascular risk in renal patients; a\u00a0new take on old tale. Front Cell Dev Biol. 2019;7:314.","journal-title":"Front Cell Dev Biol"},{"issue":"8","key":"1812_CR29","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski\u00a0P, Voors\u00a0AA, Anker\u00a0SD, Bueno\u00a0H, Cleland\u00a0JGF, Coats\u00a0AJS, et\u00a0al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891\u2013975.","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"1812_CR30","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey\u00a0AS, Stevens\u00a0LA, Schmid\u00a0CH, Zhang\u00a0YL, Castro\u00a0AF 3rd, Feldman\u00a0HI, et\u00a0al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"key":"1812_CR31","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/ki.2013.444","volume":"85","author":"A Levin","year":"2014","unstructured":"Levin\u00a0A, Stevens\u00a0PE. Summary of\u00a0KDIGO\u00a02012 CKD Guideline: behind the scenes, need for guidance, and a\u00a0framework for moving forward. Kidney Int. 2014;85:49\u201361.","journal-title":"Kidney Int"},{"issue":"7","key":"1812_CR32","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1007\/s00277-019-03708-9","volume":"98","author":"P Strati","year":"2019","unstructured":"Strati\u00a0P, Abdelrahim\u00a0M, Selamet\u00a0U, Page\u00a0VD, Pierce\u00a0SA, Verstovsek\u00a0S, et\u00a0al. Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis. Ann Hematol. 2019;98(7):1611\u20136.","journal-title":"Ann Hematol"},{"issue":"3","key":"1812_CR33","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s12185-020-02898-7","volume":"112","author":"I Kre\u010dak","year":"2020","unstructured":"Kre\u010dak\u00a0I, Holik\u00a0H, Martina\u00a0MP, Zekanovi\u0107\u00a0I, Coha\u00a0B, Gveri\u0107-Kre\u010dak\u00a0V. Chronic kidney disease could be a\u00a0risk factor for thrombosis in essential thrombocythemia and polycythemia vera. Int J Hematol. 2020;112(3):377\u201384.","journal-title":"Int J Hematol"},{"issue":"12","key":"1812_CR34","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1007\/s00277-020-04239-4","volume":"99","author":"M Lucijanic","year":"2020","unstructured":"Lucijanic\u00a0M, Galusic\u00a0D, Krecak\u00a0I, et\u00a0al. Reduced renal function strongly affects survival and thrombosis in patients with myelofibrosis. Ann Hematol. 2020;99(12):2779\u20132785.","journal-title":"Ann Hematol"},{"issue":"1","key":"1812_CR35","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1053\/j.ajkd.2003.09.026","volume":"43","author":"AD Rule","year":"2004","unstructured":"Rule\u00a0AD, Gussak\u00a0HM, Pond\u00a0GR, Bergstralh\u00a0EJ, Stegall\u00a0MD, Cosio\u00a0FG, et\u00a0al. Measured and estimated GFR in healthy potential kidney donors. Am J Kidney Dis. 2004;43(1):112\u20139.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"1812_CR36","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1186\/s12882-018-1126-8","volume":"19","author":"A Fenton","year":"2018","unstructured":"Fenton\u00a0A, Montgomery\u00a0E, Nightingale\u00a0P, Peters\u00a0AM, Sheerin\u00a0N, Wroe\u00a0AC, et al. Glomerular filtration rate: new age- and gender-specific reference ranges and thresholds for living kidney donation. BMC Nephrol. 2018;19(1):336.","journal-title":"BMC Nephrol"},{"issue":"2","key":"1812_CR37","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1159\/000477946","volume":"42","author":"FY Hsu","year":"2017","unstructured":"Hsu\u00a0FY, Lin\u00a0FJ, Ou\u00a0HT, Huang\u00a0SH, Wang\u00a0CC. Renoprotective effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in diabetic patients with proteinuria. Kidney Blood Press Res. 2017;42(2):358\u201368.","journal-title":"Kidney Blood Press Res"},{"issue":"5","key":"1812_CR38","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1046\/j.1523-1755.2000.00031.x","volume":"57","author":"MW Taal","year":"2000","unstructured":"Taal\u00a0MW, Brenner\u00a0BM. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int. 2000;57(5):1803\u201317.","journal-title":"Kidney Int"},{"issue":"28","key":"1812_CR39","doi-asserted-by":"publisher","first-page":"4385","DOI":"10.2174\/138161212802481282","volume":"18","author":"D Di Raimondo","year":"2012","unstructured":"Di Raimondo\u00a0D, Tuttolomondo\u00a0A, Butt\u00e0\u00a0C, Miceli\u00a0S, Licata\u00a0G, Pinto\u00a0A. Effects of ACE-inhibitors and angiotensin receptor blockers on inflammation. Curr Pharm Des. 2012;18(28):4385\u2013413.","journal-title":"Curr Pharm Des"},{"issue":"1","key":"1812_CR40","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/sj.jhh.1002101","volume":"21","author":"P Dandona","year":"2007","unstructured":"Dandona\u00a0P, Dhindsa\u00a0S, Ghanim\u00a0H, Chaudhuri\u00a0A. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J\u00a0Hum Hypertens. 2007;21(1):20\u20137.","journal-title":"J Hum Hypertens"},{"key":"1812_CR41","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1182\/blood-2011-11-394775","volume":"119","author":"HC Hasselbalch","year":"2012","unstructured":"Hasselbalch\u00a0HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a\u00a0trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood. 2012;119:3219\u201325.","journal-title":"Blood"},{"issue":"1","key":"1812_CR42","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach\u00a0F, Baigent\u00a0C, Catapano\u00a0AL, Koskinas\u00a0KC, Casula\u00a0M, Badimon\u00a0L, et\u00a0al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart\u00a0J. 2020;41(1):111\u201388.","journal-title":"Eur Heart J"},{"issue":"Supplement 1","key":"1812_CR43","doi-asserted-by":"publisher","first-page":"4865","DOI":"10.1182\/blood-2018-99-119118","volume":"132","author":"N Podoltsev","year":"2018","unstructured":"Podoltsev\u00a0N, Zhu\u00a0M, Wang\u00a0R, Zeidan\u00a0AM, Wang\u00a0X, Huntington\u00a0SF, et al. Use of Statins, survival and incidence of thrombosis among older adults with essential thrombocythemia: a population-based study. Blood. 2018;132(Supplement 1):4865.","journal-title":"Blood"},{"issue":"11","key":"1812_CR44","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/sj.jhh.1001748","volume":"18","author":"VG Athyros","year":"2004","unstructured":"Athyros\u00a0VG, Mikhailidis\u00a0DP, Papageorgiou\u00a0AA, Bouloukos\u00a0VI, Pehlivanidis\u00a0ANA, et\u00a0al. Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. J\u00a0Hum Hypertens. 2004;18(11):781\u20138.","journal-title":"J Hum Hypertens"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-021-01812-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-021-01812-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-021-01812-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T22:13:08Z","timestamp":1724451188000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-021-01812-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,8]]},"references-count":44,"journal-issue":{"issue":"15-16","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1812"],"URL":"https:\/\/doi.org\/10.1007\/s00508-021-01812-3","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,8]]},"assertion":[{"value":"8 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"I.\u00a0Kre\u010dak, M.\u00a0Mori\u0107 Peri\u0107, I.\u00a0Zekanovi\u0107, H.\u00a0Holik, B.\u00a0Coha, V.\u00a0Gveri\u0107-Kre\u010dak, and M.\u00a0Lucijani\u0107 declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}